Search

Coronary artery thrombosis plays a major role in the acute ischemic coronary artery syndromes in which fibrinopeptide A (FPA) has proved to be a sensitive marker. The purpose of this study was to determine FPA concentrations in patients with acute coronary artery syndromes and to determine if these could serve as a short-term prognostic indicator. Single plasma FPA levels were measured in 26 patients with acute ischemic coronary artery syndromes within 24 hours of the onset of chest pain as well as in 12 patients with chronic stable angina and in 9 control subjects. Higher FPA levels were observed in patients with unstable angina whom later developed recurrence of chest pain compared to those without (8.1 +/- 3.4 vs. 3.4 +/- 2.2; p = 0.01). Neither the localization of ischemia, presence of complications, need for revascularization nor short-term prognosis (6 months) correlated with the plasma FPA concentration. Therefore, except for recurrence of chest pain in patients with unstable angina, the finding of an elevated FPA level upon admission did not provide additional information regarding clinical course and prognosis than that obtained in a detailed clinical history, physical examination and initial electrocardiogram in patients with acute ischemic artery syndromes.

The incidence of infection is increased in patients with cancer and certain hematologic disorders. We retrospectively reviewed all the patients evaluated for infection in our Hematology-Oncology unit during a six month period. The purpose of this study was to identify the most common organisms causing infection, evaluate the usefulness of tests performed as well as to determine the outcome and complications of therapy. Contrary to earlier experience the most common organisms causing bacteremia were gram-positive. Despite this finding, gram-negative organisms remained important pathogens specially of the respiratory and urine tract judging by their predominance in urine and sputum cultures. Of the commonly ordered tests, the chest X-ray was the most frequently positive test for infection and the complication rate of antibiotic therapy was 15%. We conclude that in addition to the traditional antibiotics effective against gram-negative organisms, institution of antibiotics effective against gram-positive organisms including Staphylococcus epidermides, should be considered early in the management of these patients.

Long-term experience with totally implanted catheter systems (TICS) is limited. We retrospectively evaluated the performance and long-term complications of TICS for intravenous infusion in cancer patients; 134 systems were implanted in 128 patients. The median duration of implantation was 144 weeks with 49 systems implanted for more than one year. Complications related to surgical factors included malposition of reservoir (2%), skin perforation or wound dehiscence (1.5%) and pneumothorax (less than 1%). Complications not related to surgical factors included: drug extravasation (1.5%), mechanical malfunction (1.5%), vein thrombosis (less than 1%), clotting of the reservoir or catheter (2%), skin infection (1.5%), and sepsis (less than 1%). The total complication rate was 13%. Most complications resolved spontaneously or with medical treatment and only 6 patients (4.6%) required re-implantation of a second system. We conclude that with long-term usage of TICS, the complication rate remains low, making it a safe and viable alternative for patients requiring long-term intravenous therapy.

Warfarin, a coumarin anticoagulant, acts by interfering with the hepatic synthesis of the vitamin-K-dependent clotting factors. It is used clinically in the treatment or prophylaxis of venous thrombosis and embolisms. Resistance to the effects of the coumarin and indanedione anticoagulants has been reported in rats and man, but its incidence has been defined as extremely rare. Resistance has been described as relative, acquired, or hereditary. The first well-documented case was also the first report to identify a genetic basis for this resistance. Since that time, there has been only one other study that strengthened the evidence for a hereditary transmission, and only a few other reports have suggested hereditary influence as a reason for coumarin resistance. In this report, a patient who presented with a familial-type warfarin resistance is described. A discussion of previous reports and possible mechanisms for nonfamilial warfarin resistance is also included.